TBC1D5 Antibody

What is TBC1D5 and what cellular functions does it regulate?

TBC1D5, also known as KIAA0210, is a 795 amino acid protein that functions as a GTPase-activating protein (GAP) for Rab family members. It plays a crucial role in regulating intracellular vesicle trafficking by accelerating the intrinsic rate of GTP hydrolysis, thereby downregulating the active form of Rab proteins . This regulation is essential for maintaining cellular homeostasis and proper signaling pathways.

TBC1D5 serves as a novel retromer-interacting protein that negatively regulates VPS35/29/26 recruitment and causes Rab7 to dissociate from the membrane . It bridges endosomes and autophagosomes via its C-terminal LIR motif, and is implicated in reprogramming endocytic trafficking events during starvation-induced autophagy . The protein exists in 89 kDa and 91 kDa isoforms, and the gene encoding TBC1D5 is located on human chromosome 3, a region associated with various genetic diseases and key tumor suppressor genes .

What types of TBC1D5 antibodies are available and what are their applications?

Several TBC1D5 antibodies are available for research purposes, including:

• Mouse monoclonal antibodies (e.g., E-9): These detect TBC1D5 from multiple species including mouse, rat, and human, and can be used in various applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA) .

• Rabbit polyclonal antibodies (e.g., 17078-1-AP): These also recognize TBC1D5 across multiple applications and have been validated in various research publications .

These antibodies are available in multiple formats:

• Non-conjugated forms

• Agarose-conjugated for immunoprecipitation

• HRP-conjugated for direct detection in western blotting

• Fluorophore-conjugated forms (FITC, PE, Alexa Fluor) for immunofluorescence applications

What are the optimal sample preparation techniques for TBC1D5 detection?

For optimal TBC1D5 detection, consider the following sample preparation approaches:

• For Western Blotting:

  • Use RIPA buffer with protease inhibitors for cell lysis

  • Sonicate briefly to shear DNA and reduce viscosity

  • Centrifuge at high speed (14,000g) to remove insoluble material

  • Load 20-40 μg of total protein per lane

  • Include reducing agents in sample buffer as TBC1D5 contains disulfide bonds

• For Immunofluorescence:

  • Fix cells with 4% paraformaldehyde (10-15 minutes)

  • Permeabilize with 0.1-0.5% Triton X-100

  • Block with 5% normal serum from the same species as the secondary antibody

  • Optimize primary antibody dilution (typically 1:100-1:500)

  • Include appropriate controls to verify specificity

• For Immunoprecipitation:

  • Use milder lysis buffers (e.g., NP-40 or Digitonin-based) to preserve protein-protein interactions

  • Pre-clear lysates with Protein A/G-Sepharose

  • Use 2-5 μg of antibody per 500 μg of total protein

  • Perform overnight incubation at 4°C

How can I design experiments to study TBC1D5's interaction with the retromer complex?

When investigating TBC1D5's interaction with the retromer complex, consider these experimental approaches:

• Co-immunoprecipitation (Co-IP):

  • Use TBC1D5 antibodies to pull down associated retromer components (VPS35, VPS29, SNX1/2, SNX5/6)

  • Conversely, use antibodies against retromer components to co-precipitate TBC1D5

  • Include appropriate negative controls (IgG or unrelated antibodies)

  • Validate interactions using reciprocal Co-IPs

• Proximity Ligation Assay (PLA):

  • This technique can detect protein-protein interactions in situ

  • Use antibodies against TBC1D5 and retromer components from different species

  • Signals indicate close proximity (<40 nm) between proteins

• Genetic Manipulation:

  • Use siRNA to knock down TBC1D5 and observe effects on retromer distribution

  • Overexpress wild-type or mutant TBC1D5 to assess functional consequences

  • As demonstrated in cardiomyocyte research, TBC1D5 knockdown affects CI-MPR levels and retromer function

• Subcellular Fractionation:

  • Separate cellular compartments to track TBC1D5 and retromer components

  • Analyze changes in distribution under different conditions (e.g., starvation, ischemia)

What approaches can resolve contradictory findings regarding TBC1D5's role in retromer function?

The regulatory role of TBC1D5 in the retromer complex remains controversial . To address contradictory findings:

• Cell Type-Specific Analysis:

  • Compare TBC1D5 function across different cell types

  • Cardiomyocytes show distinct TBC1D5-dependent mechanisms during ischemia

  • Other tissues may exhibit different regulatory patterns

• Domain-Specific Mutants:

  • Generate TBC1D5 constructs with mutations in specific functional domains

  • Assess which domains are critical for retromer interaction

  • Investigate whether different domains mediate different aspects of retromer regulation

• Conditional Knockout Models:

  • Develop tissue-specific or inducible TBC1D5 knockout systems

  • Evaluate acute versus chronic loss of TBC1D5

  • Compare phenotypes across different physiological contexts

• Quantitative Proteomic Analysis:

  • Use SILAC or TMT labeling to quantify changes in protein interactions

  • Identify condition-specific TBC1D5 binding partners

  • Map the dynamic interactome under different cellular stresses

How can I optimize FRAP assays to study Rab7 membrane cycling in relation to TBC1D5?

Fluorescence Recovery After Photobleaching (FRAP) assays are valuable for studying Rab7 membrane cycling. Based on the research described in the search results :

• Plasmid Construction:

  • Use fluorescently tagged Rab7 (e.g., Scarlet-tagged Rab7 adenovirus)

  • Consider dual-color approaches with labeled TBC1D5 to track co-dynamics

• Experimental Parameters:

  • Bleach a defined region of interest containing Rab7-positive structures

  • Capture pre-bleach images as baseline

  • Monitor recovery at appropriate intervals (e.g., every 5 seconds for 5 minutes)

  • Plot recovery as percentage of pre-bleach intensity

• Manipulation Strategies:

  • Compare Rab7 cycling in control vs. TBC1D5 knockdown conditions

  • Assess the effect of TBC1D5 overexpression on recovery rates

  • As shown in cardiomyocyte studies, TBC1D5 loss leads to decelerated Rab7 membrane recycling, while overexpression reverses this effect

• Analysis Approaches:

  • Calculate mobile fraction (maximum recovery percentage)

  • Determine half-time of recovery (t½)

  • Compare recovery curves across experimental conditions

  • Correlate FRAP parameters with functional outcomes

How can TBC1D5 antibodies be utilized to study ischemic cardiac injury?

Research has demonstrated that ischemia induces significant loss of TBC1D5 in cardiomyocytes, blocking retrograde transport and decreasing CI-MPR levels . To investigate this:

• Ischemia/Hypoxia (I/H) Models:

  • Establish appropriate in vitro or in vivo I/H models

  • Monitor TBC1D5 protein levels using western blotting before and after I/H treatment

  • Compare wild-type vs. TBC1D5-overexpressing systems under I/H conditions

• Retrograde Transport Assessment:

  • Use CI-MPR as a marker for retrograde transport efficiency

  • Employ immunofluorescence to visualize CI-MPR distribution

  • Quantify colocalization with various organelle markers

• Intervention Strategies:

  • Test whether TBC1D5 restoration alleviates I/H-induced trafficking defects

  • Assess downstream effects on lysosomal cathepsin trafficking

  • Evaluate cardioprotective potential of TBC1D5-targeted therapies

• Mechanistic Analysis:

  • Investigate how TBC1D5 regulates retromer through Rab7

  • Examine connections between retromer and the cytoskeletal system

  • Assess the impact on microtubule association and dynactin p150glued interaction

What methods can best evaluate TBC1D5's role in lysosomal cathepsin trafficking?

TBC1D5 influences the trafficking of lysosomal cathepsins through regulation of CI-MPR. To study this:

• Cathepsin Trafficking Assays:

  • Monitor the localization of cathepsins B and D using immunofluorescence

  • Quantify colocalization with lysosomal markers (e.g., LAMP1)

  • Compare trafficking efficiency in TBC1D5 knockdown vs. overexpressing cells

• Pulse-Chase Experiments:

  • Label newly synthesized cathepsins and track their movement to lysosomes

  • Assess the kinetics of cathepsin maturation under different TBC1D5 conditions

  • Evaluate whether TBC1D5 manipulation affects processing time

• Activity-Based Probes:

  • Use fluorescent activity-based probes to measure functional cathepsin activity

  • Determine whether altered trafficking affects enzymatic activation

  • Correlate activity levels with TBC1D5 expression

• Super-Resolution Microscopy:

  • Employ techniques like STORM or STED to visualize cathepsin trafficking at nanoscale resolution

  • Track individual transport vesicles in real-time

  • Examine the dynamics of cathepsin sorting at the trans-Golgi network

How should I validate TBC1D5 antibody specificity for my experimental system?

Proper validation of TBC1D5 antibodies is critical for research integrity:

• Positive and Negative Controls:

  • Use lysates from cells known to express or lack TBC1D5

  • Include TBC1D5 knockdown samples as negative controls

  • Test recombinant TBC1D5 protein as a positive control

• Multiple Antibody Approach:

  • Compare results using antibodies from different sources or clones

  • Verify that different antibodies recognize the same-sized band in western blots

  • Confirm similar staining patterns in immunofluorescence

• Blocking Peptide Competition:

  • Pre-incubate antibody with excess TBC1D5 peptide antigen

  • Verify signal disappearance in blocked samples

  • Compare with unblocked antibody on identical samples

• Genetic Validation:

  • Use CRISPR/Cas9 to generate TBC1D5 knockout cells

  • Confirm absence of signal in knockout samples

  • Rescue experiments with exogenous TBC1D5 should restore signal

What are the key considerations for optimizing TBC1D5 western blotting protocols?

For optimal western blotting results with TBC1D5 antibodies:

• Sample Preparation:

  • TBC1D5 exists as 89 kDa and 91 kDa isoforms

  • Use appropriate gel percentage (8-10% acrylamide) for optimal resolution

  • Include phosphatase inhibitors if studying phosphorylation status

• Transfer Conditions:

  • For these higher molecular weight proteins, use wet transfer methods

  • Transfer at lower voltage for longer duration (e.g., 30V overnight)

  • Verify transfer efficiency with Ponceau S staining

• Antibody Optimization:

  • Titrate primary antibody concentration (typically 1:500-1:2000)

  • Extended primary antibody incubation (overnight at 4°C) may improve signal

  • HRP-conjugated TBC1D5 antibodies may provide direct detection with improved sensitivity

• Signal Detection:

  • Use enhanced chemiluminescence (ECL) substrates appropriate for the expected signal intensity

  • Consider fluorescent western blotting for more quantitative analysis

  • When using conjugated antibodies, ensure compatible detection systems are available

What are effective strategies for enhancing signal-to-noise ratio in TBC1D5 immunofluorescence?

To improve immunofluorescence results with TBC1D5 antibodies:

• Fixation Optimization:

  • Compare different fixatives (paraformaldehyde, methanol, or combination)

  • Optimize fixation duration and temperature

  • Test whether antigen retrieval improves detection

• Blocking Considerations:

  • Use appropriate blocking solutions containing BSA or normal serum

  • Extended blocking (2+ hours) may reduce background

  • Include detergents at appropriate concentrations to reduce non-specific binding

• Antibody Selection:

  • Consider directly conjugated TBC1D5 antibodies (FITC, PE, or Alexa Fluor conjugates)

  • For co-localization studies, ensure appropriate species compatibility

  • Titrate antibody concentrations to find optimal signal-to-noise ratio

• Imaging Parameters:

  • Use appropriate filter sets matching fluorophore spectra

  • Optimize exposure settings to prevent saturation

  • Employ deconvolution or structured illumination for improved resolution

How might TBC1D5 antibodies contribute to understanding autophagy regulation?

TBC1D5 bridges endosomes and autophagosomes via its C-terminal LIR motif and is implicated in reprogramming endocytic trafficking during starvation-induced autophagy . To explore this function:

• Autophagy Induction Models:

  • Monitor TBC1D5 localization under starvation conditions

  • Assess interactions with autophagy proteins (e.g., ATG proteins)

  • Evaluate the impact of TBC1D5 manipulation on autophagosome formation

• Multifaceted Imaging Approaches:

  • Use live-cell imaging with fluorescently tagged TBC1D5 and autophagy markers

  • Perform time-lapse microscopy to track dynamic interactions

  • Implement super-resolution techniques to visualize membrane contacts

• Selective Autophagy Analysis:

  • Investigate TBC1D5's role in specific forms of selective autophagy (e.g., mitophagy)

  • Research suggests TBC1D5 may be involved in RAB7-dependent mitophagy

  • Determine whether TBC1D5 functions differently across autophagy subtypes

• Therapeutic Implications:

  • Explore whether TBC1D5 modulation could enhance beneficial autophagy responses

  • Assess potential in neurodegenerative diseases where autophagy dysfunction occurs

  • Investigate connections to cancer contexts where autophagy plays dual roles

What novel methodologies are being developed for studying TBC1D5 dynamics?

Emerging technologies offer new approaches to study TBC1D5:

• Macrocyclic Peptides:

  • Recent research has developed de novo macrocyclic peptides for inhibiting, stabilizing, and probing retromer function

  • These tools could provide temporal control over TBC1D5-retromer interactions

• BioID/TurboID Proximity Labeling:

  • Fusing TBC1D5 to biotin ligases enables mapping of its proximity interactome

  • This approach has revealed interactions between autophagy components, such as ATG9A with ATG13-ATG101

  • Similar approaches could uncover novel TBC1D5 interaction partners

• Optogenetic Control Systems:

  • Light-inducible TBC1D5 recruitment or degradation systems

  • Allows precise temporal control of TBC1D5 function

  • Can help dissect acute versus chronic effects of TBC1D5 loss

• Advanced Cryo-EM Studies:

  • Structural studies of TBC1D5 in complex with retromer components

  • May resolve controversies regarding mechanism of action

  • Could inform structure-based drug design for targeting this pathway